Screener
Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $23.77M-12.7% | $27.61M+24.8% | $21.21M-7.3% | $19.86M-6.5% | $27.22M+16.6% | ||
| $21.93M+40.2% | $16.17M+3.1% | $15.39M-10.0% | $16.17M-9.3% | $15.64M-27.7% | ||
| $45.69M+6.6% | $43.78M+15.8% | $36.61M-8.5% | $36.03M-52.6% | $42.86M-43.1% | ||
| -$45.69M-6.6% | -$43.78M-15.8% | -$36.61M+10.0% | -$36.03M+52.4% | -$42.86M+43.8% | ||
| $2.27M+60.5% | $2.5M+31.6% | $3.65M+47.7% | $1.64M-44.5% | $1.41M-60.6% | ||
| —— | —— | -$32.95M+13.7% | -$34.39M+52.7% | -$41.44M+43.0% | ||
| —— | —— | $46K+107% | $0— | $0— | ||
| -$43.42M-4.8% | -$41.28M-15.0% | -$33M+12.1% | -$34.39M+52.7% | -$41.44M+43.0% | ||
| -$0.39+15.2% | -$0.37+11.9% | -$0.28+48.1% | -$0.37+65.4% | -$0.46+57.0% | ||
| -$45.65M-6.9% | -$43.68M-16.0% | -$36.5M+9.9% | -$35.91M+52.4% | -$42.72M+43.9% | ||
| -$45.69M-6.6% | -$43.78M-15.8% | -$36.61M+10.0% | -$36.03M+52.4% | -$42.86M+43.8% |
FAQ
- Is Amylyx Pharmaceuticals, Inc. profitable?
- Amylyx Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $152.1M over the trailing twelve months, a -45096.2% net margin.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- What is Amylyx Pharmaceuticals, Inc.'s earnings per share?
- Amylyx Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.